Search results
Roche Holding (VTX:ROG) investors are sitting on a loss of 19% if they invested a year ago
Simply Wall St. via Yahoo Finance· 8 months agoThe simplest way to benefit from a rising market is to buy an index fund. Active investors aim to...
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
Zacks via Yahoo Finance· 9 months agoRoche RHHBY announced that the European Commission (“EC”) had approved the label expansion for...
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
Zacks via Yahoo Finance· 10 months agoRoche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging...
Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal
Zacks via Yahoo Finance· 9 months agoRoche Holding AG RHHBY announced that the late-stage study evaluating Alecensa (alectinib) met its...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli...
Zacks via Yahoo Finance· 3 weeks agoFor Immediate Releases Chicago, IL – May 20, 2024 – Zacks.com announces the list of stocks featured...
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
Zacks via Yahoo Finance· 1 year agoRoche Holding AG RHHBY announced a collaboration with Eli Lilly and Company LLY where the latter...
Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion
Zacks via Yahoo Finance· 1 year agoRoche RHHBY announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
Roche's (RHHBY) Lunsumio Application Gets Priority Review
Zacks via Yahoo Finance· 2 years agoRoche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory...
Roche Holding's (VTX:ROG) investors will be pleased with their favorable 47% return over the last...
Simply Wall St. via Yahoo Finance· 2 years agoGenerally speaking the aim of active stock picking is to find companies that provide returns that...
Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma
Zacks via Yahoo Finance· 1 year agoRoche RHHBY announced that the FDA approved intravenously-administered Lunsumio (mosunetuzumab) for...